24/7 Market News Snapshot 02 April, 2025 – Quoin Pharmaceuticals, Ltd. American Depositary Shares (NASDAQ:QNRX)

April 2, 2025

DENVER, Colo., 02 April, 2025 (247marketnews.com) – (NASDAQ:QNRX) are discussed in this article.
Quoin Pharmaceuticals, Ltd. is currently witnessing a notable rise in its stock price, trading at $0.250 in the pre-market session, which represents an 18.15% increase from the previous close of $0.212. This surge is accompanied by an impressive trading volume of 6.00 million shares, reflecting heightened investor interest. Technical analysis indicates strong upward momentum, supported by positive market sentiment and bullish signals evident in momentum oscillators, while moving averages may suggest a probable continuation of this trend. Investors are advised to closely monitor key resistance levels and volume patterns to gain insights into prospective price movements.

In a significant development, Quoin announced promising outcomes from its ongoing clinical trial exploring the efficacy of QRX003 for treating Netherton Syndrome, a rare genetic skin disorder. Initial results reveal that after six weeks of whole-body application, the first patient in the study has almost fully recovered skin integrity. Remarkably, this patient has ceased the use of previously required medications, including antibiotics, antivirals, antihistamines, and glucocorticoids, and they have experienced a dramatic reduction in pruritus, resulting in a newfound ability to sleep uninterrupted.

Dr. Michael Myers, CEO of Quoin Pharmaceuticals, expressed his satisfaction with the clinical progress observed. He emphasized that the ongoing improvements underline QRX003’s potential to effectively address the core challenges associated with Netherton Syndrome, thereby enhancing patient quality of life without the burdens of heavy sedation. Following the encouraging results, the company has secured approval to initiate whole-body applications of QRX003 in a second pediatric patient, with further studies aimed at including additional subjects. Quoin Pharmaceuticals remains optimistic about QRX003’s implications in advancing treatment options for patients with rare disorders. Regular updates on patient progress are expected as the study advances.

Related news for (QNRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.